🌍 NLS Pharmaceutics Ltd. (NLSPW) - Form 6-K Filing
Filing Date: 2025-10-30
Accepted: 2025-10-30 07:15:20
Event Type: Clinical Trial Update
Event Details:
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs Supported by Solid Cash Position and Strategic Funding Outlook.
💼 Business Developments:
✅ Partnership/Collaboration
❌ Acquisition Activity: Not reported
✅ Licensing Agreement
✅ Regulatory Milestone
❌ Leadership Updates: Not reported
📞 Contact Information:
Media Contact: s NLS Pharmaceutics Ltd. – InvestorRelations@nls-pharma.com Aexon Labs – info@ae
🌍 NLS Pharmaceutics Ltd. (NLSPW) - Form 6-K Filing
Filing Date: 2025-10-30
Accepted: 2025-10-30 07:15:20
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: